Gene Therapy for Parkinson’s: Disease from Bench to Bedside

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Unknown venue

• Publication date

  2012-10-09

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1201/B12948-92
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Lentivirus-mediated transgene delivery to the hippocampus reveals sub-field specific differences in expression

  2009cited by this paper
• Scientific rationale for the development of gene therapy strategies for Parkinson's disease.

  2009cited by this paper
• Efficient gene delivery to the adult and fetal CNS using pseudotyped non-integrating lentiviral vectors

  2009cited by this paper
• Gene therapy for neurological disorders: challenges and future prospects for the use of growth factors for the treatment of Parkinson's disease.

  2009cited by this paper
• Regulatable promoters and gene therapy for Parkinson's disease: is the only thing to fear, fear itself?

  2008cited by this paper
• The effect of α‐synuclein knockdown on MPP+ toxicity in models of human neurons

  2008cited by this paper
• RNA interference mediated silencing of α-synuclein in MN9D cells and its effects on cell viability

  2008cited by this paper
• Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial.

  2007cited by this paper
• Parkin protects against neurotoxicity in the 6-hydroxydopamine rat model for Parkinson's disease.

  2006cited by this paper
• RNA knockdown as a potential therapeutic strategy in Parkinson's disease

  2006cited by this paper
• Inhibition of the cdk5/p25 fragment formation may explain the antiapoptotic effects of melatonin in an experimental model of Parkinson's disease

  2006cited by this paper
• Increased utility in the CNS of a powerful neuron‐specific tetracycline‐regulatable adenoviral system developed using a post‐transcriptional enhancer

  2005cited by this paper
• Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease.

  2005cited by this paper
• Delivery of GDNF by an E1,E3/E4 deleted adenoviral vector and driven by a GFAP promoter prevents dopaminergic neuron degeneration in a rat model of Parkinson's disease

  2004cited by this paper
• [123I]β-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson’s disease

  2003cited by this paper
• α‐Synuclein protects naive but not dbcAMP‐treated dopaminergic cell types from 1‐methyl‐4‐phenylpyridinium toxicity

  2003cited by this paper
• Self-complementary adeno-associated virus serotype 2 vector: global distribution and broad dispersion of AAV-mediated transgene expression in mouse brain.

  2003cited by this paper
• Immune responses to adeno-associated virus and its recombinant vectors

  2003cited by this paper
• Are ubiquitination pathways central to Parkinson's disease?

  2003cited by this paper
• Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease

  2002cited by this paper
• Striatal 6-hydroxydopamine induces apoptosis of nigral neurons in the adult rat.

  2002cited by this paper
• Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of l-dopa using rAAV-mediated gene transfer

  2002cited by this paper
• Immunology of viral-vector-mediated gene transfer into the brain: an evolutionary and developmental perspective.

  2002cited by this paper
• Persistent changes in striatal gene expression induced by long‐term l‐DOPA treatment in a rat model of Parkinson's disease

  2001cited by this paper
• Cell death inhibition: keeping caspases in check.

  2001cited by this paper
• CMV-β-Actin Promoter Directs Higher Expression from an Adeno-Associated Viral Vector in the Liver than the Cytomegalovirus or Elongation Factor 1α Promoter and Results in Therapeutic Levels of Human Factor X in Mice

  2001cited by this paper
• Growth and Functional Efficacy of Intrastriatal Nigral Transplants Depend on the Extent of Nigrostriatal Degeneration

  2001cited by this paper
• Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies

  2001cited by this paper
• HIV-2 and SIV Vector Systems

  2001cited by this paper
• Parkinson disease gene therapy moves toward the clinic

  2000cited by this paper
• Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.

  2000cited by this paper
• Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach.

  2000cited by this paper
• Tetracycline-regulated gene expression in the brain.

  2000cited by this paper
• Long-term doxycycline-controlled expression of human tyrosine hydroxylase after direct adenovirus-mediated gene transfer to a rat model of Parkinson's disease.

  1999cited by this paper
• "Global" cell replacement is feasible via neural stem cell transplantation: evidence from the dysmyelinated shiverer mouse brain.

  1999cited by this paper
• Vesicular Monoamine Transporter-2 and Aromaticl-Amino Acid Decarboxylase Enhance Dopamine Delivery afterl-3,4-Dihydroxyphenylalanine Administration in Parkinsonian Rats

  1999cited by this paper
• Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease.

  1999cited by this paper
• Subthalamic nucleus lesions induce deficits as well as benefits in the hemiparkinsonian rat

  1999cited by this paper
• Differential Regulation of Striatal Preproenkephalin and Preprotachykinin mRNA Levels in MPTP‐Lesioned Monkeys Chronically Treated with Dopamine D1 or D2 Receptor Agonists

  1999cited by this paper
• Astrocyte-specific expression of tyrosine hydroxylase after intracerebral gene transfer induces behavioral recovery in experimental Parkinsonism

  1998cited by this paper
• Expression of the proto-oncogene Ret, a component of the GDNF receptor complex, persists in human substantia nigra neurons in Parkinson's disease.

  1998cited by this paper
• Neurotrophins prevent death and differentially affect tyrosine hydroxylase of adult rat nigrostriatal neurons in vivo.

  1998cited by this paper
• An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene.

  1998cited by this paper
• Dopamine turnover and metabolism in the striatum of parkinsonian rats grafted with genetically-modified human astrocytes.

  1998cited by this paper
• Neurturin Exerts Potent Actions on Survival and Function of Midbrain Dopaminergic Neurons

  1998cited by this paper
• Intrastriatal Grafting of Cos Cells Stably Expressing Human Aromatic l‐Amino Acid Decarboxylase: Neurochemical Effects

  1997cited by this paper
• Construction of adenovirus vectors through Cre-lox recombination

  1997cited by this paper
• Role of Aromatic l‐Amino Acid Decarboxylase for Dopamine Replacement by Genetically Modified Fibroblasts in a Rat Model of Parkinson's Disease

  1997cited by this paper
• Stimulation of subthalamic nucleus alleviates tremor in Parkinson's disease.

  1997cited by this paper
• Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease.

  1997cited by this paper
• In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector

  1996cited by this paper
• Generation of DOPA-producing astrocytes by retroviral transduction of the human tyrosine hydroxylase gene: in vitro characterization and in vivo effects in the rat Parkinson model.

  1996cited by this paper
• Immune responses to adenovirus vectors in the nervous system.

  1996cited by this paper
• Astrocytes retrovirally transduced with BDNF elicit behavioral improvement in a rat model of Parkinson's disease.

  1995cited by this paper
• Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease.

  1995cited by this paper
• Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation

  1995cited by this paper
• The primate subthalamic nucleus. I. Functional properties in intact animals.

  1994cited by this paper
• The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease.

  1994cited by this paper
• Long-term survival of autologous muscle grafts in rat brain.

  1992cited by this paper
• A Clinically Relevant Unilateral Rat Model of Parkinsonian Akinesia

  1992cited by this paper
• BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra

  1991cited by this paper
• Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce L-dopa.

  1991cited by this paper
• Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.

  1990cited by this paper
• Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease.

  1989cited by this paper
• Aromatic L‐amino acid decarboxylase in rat corpus striatum

  1981cited by this paper
• The site of dopamine formation in rat striatum after L-dopa administration.

  1981cited by this paper
• Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour.

  1971cited by this paper

• No citing papers are available for this paper.